RxDoctor Payments Data

Deana McCarty

Nurse Practitioner · Bastian, VANPI 1821541889

Payments from drug & device makers

$491in general payments, 2019–2025

Across 25 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$126
  • Exact Sciences$107
  • AbbVie$64
  • Astellas Pharma US Inc$32
  • Biogen$29
  • Boehringer Ingelheim$24
  • plus $109 from 7 others

What the payments were for

  • Food & beverage$491100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$491 in reported general payments places this provider in the 75th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$2,367
Medicare patients
50
Services billed
115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol70$67,101
OzempicSemaglutide47$62,469
MounjaroTirzepatide34$38,149
Invega SustennaPaliperidone Palmitate11$37,115
LinzessLinaclotide26$33,978
EliquisApixaban32$32,285
TrulicityDulaglutide27$27,540
JardianceEmpagliflozin16$24,723
RybelsusSemaglutide15$20,559
JanuviaSitagliptin Phosphate13$20,310
TradjentaLinagliptin16$18,123
VascepaIcosapent Ethyl18$15,597
XareltoRivaroxaban17$13,793
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$12,207
Praluent PenAlirocumab14$8,523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Bevespi Aerosphere$12$93,374119 claims
Novo NordiskOzempic, Rybelsus$126$83,02762 claims
Boehringer IngelheimJardiance, Tradjenta$24$42,84632 claims
AbbVieLinzess, Synthroid$64$35,60059 claims
PfizerEliquis$12$32,28532 claims
MerckJanuvia$16$20,31013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Bastian

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →